Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Leads Second Tranche of Sagimet's $25 Million Financing

publication date: Aug 5, 2019

Ascletis Pharma of Hangzhou led a second tranche of a Series E financing for the Bay Area's Sagimet that brings the financing to $25 million. Ascletis, which also led the first tranche, acquired China rights to Sagimet's novel non-alcoholic steatohepatitis (NASH) candidate as part of the deal. In April 2019, Sagimet dosed the first patient in a US-China Phase II trial of the FASN (fatty acid synthase) inhibitor, TVB-2640. Ascletis focuses on viral, cancer and fatty liver diseases with two treatments for hepatitis C approved in China. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here